Who is Orforglipron suitable for?
Orforglipron has been studied and approved for weight management in adults with obesity, or with overweight in combination with at least one weight-related condition. The precise indication criteria (including BMI limits) and the assessment of whether the drug is suitable for your situation can be found on the Foundayo page.
The definitive indication for the Netherlands will follow after European approval.
How Orforglipron works
Orforglipron acts as a GLP-1 receptor agonist: it mimics the body's own GLP-1 hormone. This hormone plays a role in:
- Regulation of blood sugar levels
- Reduction of appetite
- Delayed gastric emptying
For a complete overview of the effects on weight loss and blood sugar, and the dosage build-up schedule, please refer to the Foundayo page, where the mechanism of action is described based on the approved product information.
Orforglipron side effects
The side effects of orforglipron are similar to those of other GLP-1 medicines. Most affect the digestive system, especially at the start of treatment and after each dose increase, and usually decrease over time.
- Very common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain
- Common: headache, bloating, belching, reflux, gas, fatigue, hair loss, dizziness
- Rare but serious: pancreatitis, gallbladder problems, low blood sugar, allergic reaction
Orforglipron should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. For the full overview, including when to contact a doctor, see the Foundayo page.
Orforglipron approval status
Orforglipron was approved under the brand name Foundayo® by the US FDA (April 2026) and the UK MHRA (August 2026). On 15 October 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval in the EU for weight management and type 2 diabetes. The final decision lies with the European Commission. After that, each country sets its own price and reimbursement, so it is not yet known when orforglipron will be available in the Netherlands.
The safety and effectiveness of orforglipron are substantiated by extensive clinical studies, including the ATTAIN research program. Complete safety information and contraindications can be found on the Foundayo page.
Orforglipron vs tirzepatide (Mounjaro) and semaglutide
The main difference is how you take it. Orforglipron is a daily tablet that you can take at any time, with or without food. Tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy) are mostly weekly injections; semaglutide is also available as a tablet (Rybelsus, Wegovy pill), but that must be taken on an empty stomach.
In studies, people taking the highest dose of orforglipron lost about 12% of their body weight after 72 weeks. With tirzepatide, weight loss in studies was higher, up to around 20%. These medicines have not been compared directly, so the figures cannot be compared one-to-one.
Orforglipron works only on the GLP-1 receptor, while tirzepatide also acts on the GIP receptor and retatrutide on three receptors.
Orforglipron reimbursement by health insurer
Because orforglipron is not yet registered in the Netherlands:
- reimbursement is currently not possible
- it is still unknown whether it will be reimbursed in the future
This depends on:
- effectiveness
- cost price
- national guidelines
Orforglipron price
There is no Dutch price for orforglipron yet, because the medicine is not yet registered in the Netherlands. In the United States, Eli Lilly sells Foundayo from $149 per month for the lowest dose for people who pay for it themselves. The price per month in the Netherlands will only be known once the tablet is approved and available here.
Orforglipron Dosage
Orforglipron is available in multiple strengths, with a titration schedule that maintains a minimum of 30 days per step. The exact dosage schedule and available strengths can be found on the Foundayo page, based on the approved product information.
When will orforglipron be available in the Netherlands?
Orforglipron is already on the market in the United States and the United Kingdom, under the brand name Foundayo®. In the EU, the CHMP gave a positive opinion on 15 October 2026; the European Commission still has to make the final decision. As soon as there is more news, you will find the current status, price and availability on our Foundayo page. There is no Dutch release date yet.
Summary
- Orforglipron is the active ingredient in Foundayo®, developed by Eli Lilly
- It is an orally administered GLP-1 receptor agonist, a unique advantage within this class of medicines
- Most common side effects: nausea, constipation, diarrhea and vomiting
- Approved in the US (April 2026) and UK (August 2026)
- Positive CHMP opinion in the EU (October 2026); not yet available in the Netherlands
- For price, availability and dosage: see the Foundayo page
